Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.
This study is an open, multicenter, prospective phase I dose escalation clinical trial followed by an expansion cohort. The aim of this study is to asses the Recommended Phase 2 Dose (R2PD) and the safety profile, among other efficacy, in FGFR1/2/3 positive, hormone receptor-positive breast cancer (HRPBC) patients with metastatic disease after progression to the combination of an aromatase inhibitor plus palbociclib, abemaciclib or ribociclib, according RECIST 1.1 criteria.
Breast Cancer Metastatic|Hormone Receptor Positive Malignant Neoplasm of Breast
DRUG: Combination, Rogaratinib + palbociclib + fulvestrant
Recommended Phase 2 Dose, Highest dose at which \<1 out of 6 patients experience a DLT., 2 months|Incidence of Treatment-Emergent Adverse Event, Percentage of patients with each adverse event., 2 years
Progression free survival, Time from the date of first dose of study treatment to the date of progression or death (from any cause)., 2 years|Pharmacokinetic interactions of fulvestrant and palbociclib over rogaratinib metabolism., Plasmatic levels of fulvestrant, palbociclib and rogaratinib, 2 years|Pharmacodynamic markers levels of FGFR1 Blockade, Plasma levels of phosphate and FGF23., 2 years|Response rate, Percentage of patients that achieve response according to RECIST 1.1 criteria., 1 year
This study is an open, multicenter, prospective phase I dose escalation clinical trial followed by an expansion cohort. The aim of this study is to asses the Recommended Phase 2 Dose (R2PD) and the safety profile, among other efficacy, in FGFR1/2/3 positive, hormone receptor-positive breast cancer (HRPBC) patients with metastatic disease after progression to the combination of an aromatase inhibitor plus palbociclib, abemaciclib or ribociclib, according RECIST 1.1 criteria.